Sprint Bioscience AB (publ)

Stockholm Stock Exchange SPRINT.ST

Sprint Bioscience AB (publ) Cash and Short-Term Investments for the year ending December 31, 2023

Sprint Bioscience AB (publ) Cash and Short-Term Investments is NA for the year ending December 31, 2023. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Stockholm Stock Exchange: SPRINT.ST

Sprint Bioscience AB (publ)

CEO	Mr. Johan Emilsson
IPO Date	Nov. 7, 2014
Location	Sweden
Headquarters	Novum
Employees	36
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.

Key trends

Past 5 years